Report card of 130 pharmaceutical companies exposed 10 with net profit or more than 1 billion

Source: minenet 2018-01-29 as of January 25, 2018, 130 pharmaceutical companies in a share disclosed their 2017 "report card", 6 for performance express and 124 for performance forecast Among them, the net profits of Lizhu group, Jilin Aodong, xinlitai, Shanghai Laishi and other 10 companies are expected to exceed 1 billion yuan Pharmaceutical enterprises (unit: 10000 yuan) whose net profit is expected to exceed 1 billion yuan in 2017, Lizhu group: the net profit ranks first According to the 2017 annual performance forecast, the net profit of Lizhu group is 4322.0717 million-4475.1744 million yuan, with a year-on-year growth rate of 451.04% - 470.56% With regard to the substantial growth of performance, Lizhu group said that the company and its subsidiary Lizhu pharmaceutical factory of Lizhu group transferred 100% equity of its subsidiary Zhuhai Weixing Industrial Co., Ltd this equity transfer was completed on July 17, 2017, and it is expected that this transaction will increase the company's net profit attributable to shareholders of listed companies by about 3.498 billion yuan In addition, the company's business sales in various fields maintain a stable growth, which is also one of the factors for the continuous and stable growth of operating revenue and profit On December 23, 2017, Lizhu group issued an announcement that dantraline sodium for injection, which had been included in the priority review earlier, was approved by CFDA for clinical application; on December 30, the announcement on the approved clinical application of the product was issued again This time, the approved injection is a recombinant all human anti RANKL monoclonal antibody injection At the same time, in the middle of December, jiankangyuan, the company's shareholder, and jiankangyuan, the company's shareholder, indirectly increased investment of 306 million yuan and 294 million yuan to Lizhu McAb through overseas SPV respectively (keeping the shareholding ratio unchanged), which will help speed up the research and development and listing of McAb products According to statistics, including the above two products, in 2017, six new products of Lizhu group were approved for clinical application At present, the company has 11 over 100 million products, and the new products will surely bring good stimulation to the company's performance after coming into the market in the future Zhifei biology: the growth rate is amazing In 2017, the performance of Zhifei biology "turned around" In the first half of the year, the net profit increased by 1326.96% year-on-year, and the annual growth is expected to be 1191.5% - 1283.75% Zhifei biology said that the uncertainty factors such as the industrial policy changes caused by the "March 18 vaccine industry event" in 2016 are gradually eliminated, the new policies of the industry have been gradually implemented, the industry environment has been further standardized and purified, and the promotion and sales of the company's own products and agents of class II vaccine products have been restored In addition, the company comprehensively carries out the production, bidding, promotion and sales of vaccine products Some brokers pointed out that Zhifei biology was the most explosive company after the vaccine incident Its R & D strength is strong, and the follow-up multi innovation, multi price and multi vaccine new products will be gradually launched to create a new profit growth point In addition, the exclusive agent of the 4-price HPV vaccine will bring huge profits to the company Jiu'An medical: the net profit of Jiu'An medical was from 10 million yuan to more than 100 million yuan in advance According to the data, the net profit of Jiu'An medical in the first half of 2017 decreased nearly 10% year on year The expected loss of the whole year is 130 million to 150 million yuan, with a change range of - 1134.63% ～ - 996.68% The net profit in 2016 was 14.4979 million yuan Jiuan medical said that it will continue to build a software and hardware integrated innovative service mode around the strategy of "entering the field of mobile medical and health big data with wearable devices and intelligent hardware as the entrance, and then establishing a health ecosystem around users" The previous fund-raising projects will continue to be built step by step The transformation of the company to mobile medical treatment has entered the critical stage, and it needs to continue to increase R & D investment It is understood that Jiuan medical has made good progress in B2B and B2C At present, it has conducted in-depth cooperation with a number of professional medical institutions at home and abroad in software and hardware equipment, cloud platform, data analysis and processing and other aspects to serve patients with chronic diseases List of 2017 pharmaceutical enterprise performance express (unit: 100 million yuan) list of 2017 pharmaceutical enterprise performance forecast (unit: 10000 yuan) source: Dongfang fortune.com